Member Info for Marty130

Arget Deal Value: While Genflow has not officially confirmed a "30 million" figure, market analysts suggest a successful commercial exit via licensing could provide non-dilutive cash that would significantly "dwarf" the company's current market capitalisation.

Arget Deal Value: While Genflow has not officially confirmed a "30 million" figure, market analysts suggest a successful commercial exit via licensing could provide non-dilutive cash that would significantly "dwarf" the company's current market capitalisation.

Iris pharma turnover

In 2020, IRIS Pharma, a French CRO specializing in ophthalmology, recorded a total turnover of €7.8 million. The company, which was acquired by ABIONYX Pharma in late 2021, is recognized for its work with over 400 international clients in preclinical and clinical studies.

Business Wire

+2

Key Financial and Company Information:

Turnover (2020): €7.8 million.

Profit (2020): €0.7 million.

Status: Acquired by ABIONYX Pharma (subsidiary).

Headquarters: Nice, France.

Specialization: Preclinical and clinical research in ophthalmology.

Genflow Biosciences (LSE:GENF) is not FDA-approved; its lead drug candidate, GF-1002, is in the preclinical stage for Metabolic Associated Steatohepatitis (MASH). The company has received guidance from the FDA via the INTERACT program (Initial Targeted Engagement for Regulatory Advice on CBER Products) to proceed with animal studies, aiming for future clinical trials.

BioSpace

+3

Key details regarding Genflow's regulatory status as of early 2026:

FDA Status: The FDA encouraged Genflow to proceed with pilot proof-of-concept (POC) studies to inform future toxicology and biodistribution studies for MASH.

Clinical Trials: Genflow is preparing for clinical trial authorization, with a particular focus on the European Medicines Agency (EMA) to start human trials.

Pipeline: The company is developing gene therapies using a variant of the SIRT6 gene to treat age-related diseases like MASH and progeria.

Animal Studies: A dog aging trial for GF-1004 has already completed, showing positive safety results.

Funding: The company secured roughly €4 million in funding from the Wallonia Region of Belgium to advance its MASH program, with funds expected in 2026.

Share price will rise substantially in the coming months, all the signs are there..

Genflow potential deal like madrigal

+2

Based on recent developments, Genflow Biosciences (LSE:GENF) is positioning its lead compound, GF-1002 (a SIRT6-based gene therapy), for a potential, high-value, non-dilutive licensing deal in the Metabolic Dysfunction-Associated Steatohepatitis (MASH/NASH) market, similar to the strategic moves made by Madrigal Pharmaceuticals.

Https://www.google.com/amp/s/stocktwits.com/news-articles/markets/equity/mdgl-stock-madrigal-ribo-sirna-mash-deal/cZb6BzDR4qi/amp

Genflow potential deal with roche in millions with animal health company

+4

As of September 2025, London-listed Genflow Biosciences PLC (LSE:GENF) has signed Confidential Disclosure Agreements (CDAs) with two "leading" animal health companies to explore potential partnerships for its longevity gene therapy, but has not officially named Roche as a partner in these specific, publicly announced discussions.

Having spent a long time researching this company, I bought a large amount of shares in genflow. Factors influencing my decision are the prospect of deals coming down the line in the coming months, and what can't be ignored is the 36% holding by Dr. Eric Leire, CEO..

My research showing mixed results from three trials. This could turn out to be hype and nothing else. Most definately not a wonder drug. Risk is too high..

No news makes Jack a dull boy..

Thanks for your reply l.. Onward and upwards..

You are not a very kind person...

I wanted to gauge opinion from those who've been invested longer then myself.

Only.5 away.

Https://www.irishtimes.com/business/2024/07/23/hvivo-chair-cathal-friel-sells-remaining-shares-for-73m/

HCT..

Exactly.

Some can't wait and selling off the recent rises....

Ex dividend is while off..